Payment overview · 2025
General Payments
$681.91
26 reported records · 9 companies
Healthcare provider profile · identity verified
Scott William Visser, MD
Allopathic & Osteopathic Physicians|Family Medicine · WILMINGTON, NC · NPI 1376629113
Verified facts
What the public records show
CMS Open Payments records show Scott William Visser, MD received $681.91 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $337.63 | 49.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.02 | 26.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.21 | 6.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.40 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.74 | 2.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.01 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.68 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.19 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.03 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $681.91 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $174.60 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $163.03 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1066 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 179 |
| Metoprolol Succinate | Metoprolol Succinate | 481 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 110 |
| Omeprazole | Omeprazole | 348 | 108 |
| Lisinopril | Lisinopril | 342 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 323 | 95 |
| Losartan Potassium | Losartan Potassium | 302 | 90 |
| Metformin Hcl Er | Metformin Hcl | 233 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 69 |
| Gabapentin | Gabapentin | 173 | 57 |
| Eliquis | Apixaban | 172 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 168 | 47 |
| Trazodone Hcl | Trazodone Hcl | 161 | 52 |
| Meloxicam | Meloxicam | 153 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 39 |
| Simvastatin | Simvastatin | 139 | 39 |
| Allopurinol | Allopurinol | 137 | 43 |
| Carvedilol | Carvedilol | 134 | 39 |
| Ezetimibe | Ezetimibe | 133 | 38 |
| Ozempic | Semaglutide | 123 | 22 |
| Sertraline Hcl | Sertraline Hcl | 117 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 36 |
| Metformin Hcl | Metformin Hcl | 107 | 29 |
| Valsartan | Valsartan | 106 | 31 |
| Furosemide | Furosemide | 103 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 29 |
| Finasteride | Finasteride | 101 | 31 |
| Mirtazapine | Mirtazapine | 97 | 20 |
| Potassium Chloride | Potassium Chloride | 97 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 24 |
| Tramadol Hcl | Tramadol Hcl | 94 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 27 |
| Montelukast Sodium | Montelukast Sodium | 85 | 25 |
| Alendronate Sodium | Alendronate Sodium | 83 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 81 | 23 |
| Prednisone | Prednisone | 76 | 57 |
| Ramipril | Ramipril | 76 | 18 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Irbesartan | Irbesartan | 74 | 21 |
| Alprazolam | Alprazolam | 71 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 18 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 18 |
| Glimepiride | Glimepiride | 63 | 18 |
| Bupropion Xl | Bupropion Hcl | 60 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 20 |
| Chlorthalidone | Chlorthalidone | 53 | 14 |
| Pregabalin | Pregabalin | 53 | 13 |
| Jardiance | Empagliflozin | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 15 |
| Lorazepam | Lorazepam | 42 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 13 |
| Spironolactone | Spironolactone | 41 | 15 |
| Memantine Hcl | Memantine Hcl | 40 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 13 |
| Cephalexin | Cephalexin | 33 | 30 |
| Estradiol | Estradiol | 33 | 16 |
| Famotidine | Famotidine | 33 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 26 |
| Atenolol | Atenolol | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Colchicine | Colchicine | 26 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Azithromycin | Azithromycin | 18 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 12 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Trandolapril | Trandolapril | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $681.91 · 26 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, FARXIGA, GVOKE HYPOPEN, NEXLETOL, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, Symbravo, VOQUEZNA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error